280 related articles for article (PubMed ID: 23988031)
1. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
2. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
[TBL] [Abstract][Full Text] [Related]
3. CD15, CD30, and PAX5 evaluation in Hodgkin's lymphoma on fine-needle aspiration cytology samples.
Cozzolino I; Vitagliano G; Caputo A; Montella M; Franco R; Ciancia G; Selleri C; Zeppa P
Diagn Cytopathol; 2020 Mar; 48(3):211-216. PubMed ID: 31825183
[TBL] [Abstract][Full Text] [Related]
4. CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL).
Ranuhardy D; Suzanna E; Sari RM; Hadisantoso DW; Andalucia R; Abdillah A
Acta Med Indones; 2018 Apr; 50(2):104-109. PubMed ID: 29950528
[TBL] [Abstract][Full Text] [Related]
5. Peripheral T-cell lymphomas expressing CD30 and CD15.
Barry TS; Jaffe ES; Sorbara L; Raffeld M; Pittaluga S
Am J Surg Pathol; 2003 Dec; 27(12):1513-22. PubMed ID: 14657710
[TBL] [Abstract][Full Text] [Related]
6. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
7. Immunoprofile of Hodgkin's lymphoma in India.
Patkar N; Mehta J; Kulkarni B; Pande R; Advani S; Borges A
Indian J Cancer; 2008; 45(2):59-63. PubMed ID: 18626150
[TBL] [Abstract][Full Text] [Related]
8. Classical Hodgkin lymphoma arising in the rectum.
Valbuena JR; Gualco G; Espejo-Plascencia I; Medeiros LJ
Ann Diagn Pathol; 2005 Feb; 9(1):38-42. PubMed ID: 15692949
[TBL] [Abstract][Full Text] [Related]
9. An Epstein-Barr virus-positive classical Hodgkin lymphoma with exclusive sinusoidal growth pattern: An unusual morphologic variant.
Su P; Jug R; Liu X; Wang E
Pathol Res Pract; 2017 Jun; 213(6):710-712. PubMed ID: 28552534
[TBL] [Abstract][Full Text] [Related]
10. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
Kim LH; Eow GI; Peh SC; Poppema S
Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
[TBL] [Abstract][Full Text] [Related]
11. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
[TBL] [Abstract][Full Text] [Related]
12. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
[TBL] [Abstract][Full Text] [Related]
13. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
15. Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.
Zhou M; Fadlelmola FM; Cohn JB; Skinnider B; Gascoyne RD; Banerjee D
Mol Cancer; 2008 Jan; 7():12. PubMed ID: 18218123
[TBL] [Abstract][Full Text] [Related]
16. CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma.
Venkataraman G; Raffeld M; Pittaluga S; Jaffe ES
Histopathology; 2011 Apr; 58(5):803-5. PubMed ID: 21457163
[No Abstract] [Full Text] [Related]
17. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: application of tissue microarray technique.
Wang J; Taylor CR
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):206-13. PubMed ID: 12966346
[TBL] [Abstract][Full Text] [Related]
19. Thyroid nodule as a first manifestation of Hodgkin lymphoma-report of two cases and literature review.
Szczepanek-Parulska E; Szkudlarek M; Majewski P; Breborowicz J; Ruchala M
Diagn Pathol; 2013 Jul; 8():116. PubMed ID: 23856094
[TBL] [Abstract][Full Text] [Related]
20. CD30 cell graphs of Hodgkin lymphoma are not scale-free--an image analysis approach.
Schäfer H; Schäfer T; Ackermann J; Dichter N; Döring C; Hartmann S; Hansmann ML; Koch I
Bioinformatics; 2016 Jan; 32(1):122-9. PubMed ID: 26363177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
